Teva In Transition: Generics, Specialty And ‘The Space Between’
Executive Summary
In an interview, President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva’s late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.